Comparison of four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors

Pradip Datta, Vicki Hinz, George Klee

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objectives: Comparison of a new monoclonal digoxin assay with three polyclonal digoxin assays for their cross-reactivity to digoxin-like immunoreactive factors (DLIF) and digoxin metabolites. Design and Methods: Sixty-six nondigitalized patient samples from 5 different groups: neonates, women in 3rd trimester pregnancy, and patients with liver or renal diseases, or undergoing organ transplants, and 139 samples from digoxin-treated patients of 4 categories (hospital sick, liver, renal, and outpatients) were compared in 4 different digoxin assays: (a) ACS(TM) Digoxin (ACS) developed for the automated chemiluminescent Ciba Corning ACS 180® system, (b) Baxter Stratus(TM) (Stratus, a fluoroimmunoassay), (c) Ciba-Corning Magic(TM) (Magic, a radioimmunoassay), and (d) an in-house radioimmunoassay (RIA). The ACS(TM) and RIA were also compared for their cross-reactivity to four principal digoxin metabolites. Results and Conclusion: Among the nondigitalized specimens, no significant DLIF interference was found for all 4 assays among the pregnant women or liver and transplant patients. However, the neonates registered high DLIF interference with Magic(TM) and RIA, but none for ACS(TM) or Stratus(TM). DLIF interference in renal samples was highest in the Magic assay and lowest in RIA. Among the specimens with digoxin, a higher number of discrepant samples were found from the sick patients than from outpatients. In 75% of such discrepant samples, the ACS(TM) result was less than other assay results, suggesting DLIF as the probable cause. The two assays differed most in their cross-reactivity to the deglycated metabolites, digoxigenin and its mono-digitoxoside.

Original languageEnglish (US)
Pages (from-to)541-547
Number of pages7
JournalClinical Biochemistry
Volume29
Issue number6
DOIs
StatePublished - Dec 1996
Externally publishedYes

Fingerprint

Digoxin
Immunoassay
Assays
Magic
Radioimmunoassay
Metabolites
Liver
Transplants
Kidney
Outpatients
Newborn Infant
Fluoroimmunoassay
Pregnancy Trimesters
digoxin-like factors
Pregnant Women

Keywords

  • Antibodies
  • Cross-reactivity
  • Digoxin immunoassays
  • Digoxin-like immunoreactive factors
  • Specificity

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Comparison of four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors. / Datta, Pradip; Hinz, Vicki; Klee, George.

In: Clinical Biochemistry, Vol. 29, No. 6, 12.1996, p. 541-547.

Research output: Contribution to journalArticle

Datta, Pradip ; Hinz, Vicki ; Klee, George. / Comparison of four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors. In: Clinical Biochemistry. 1996 ; Vol. 29, No. 6. pp. 541-547.
@article{a7ac5294588c46f39e2eaf224f0719aa,
title = "Comparison of four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors",
abstract = "Objectives: Comparison of a new monoclonal digoxin assay with three polyclonal digoxin assays for their cross-reactivity to digoxin-like immunoreactive factors (DLIF) and digoxin metabolites. Design and Methods: Sixty-six nondigitalized patient samples from 5 different groups: neonates, women in 3rd trimester pregnancy, and patients with liver or renal diseases, or undergoing organ transplants, and 139 samples from digoxin-treated patients of 4 categories (hospital sick, liver, renal, and outpatients) were compared in 4 different digoxin assays: (a) ACS(TM) Digoxin (ACS) developed for the automated chemiluminescent Ciba Corning ACS 180{\circledR} system, (b) Baxter Stratus(TM) (Stratus, a fluoroimmunoassay), (c) Ciba-Corning Magic(TM) (Magic, a radioimmunoassay), and (d) an in-house radioimmunoassay (RIA). The ACS(TM) and RIA were also compared for their cross-reactivity to four principal digoxin metabolites. Results and Conclusion: Among the nondigitalized specimens, no significant DLIF interference was found for all 4 assays among the pregnant women or liver and transplant patients. However, the neonates registered high DLIF interference with Magic(TM) and RIA, but none for ACS(TM) or Stratus(TM). DLIF interference in renal samples was highest in the Magic assay and lowest in RIA. Among the specimens with digoxin, a higher number of discrepant samples were found from the sick patients than from outpatients. In 75{\%} of such discrepant samples, the ACS(TM) result was less than other assay results, suggesting DLIF as the probable cause. The two assays differed most in their cross-reactivity to the deglycated metabolites, digoxigenin and its mono-digitoxoside.",
keywords = "Antibodies, Cross-reactivity, Digoxin immunoassays, Digoxin-like immunoreactive factors, Specificity",
author = "Pradip Datta and Vicki Hinz and George Klee",
year = "1996",
month = "12",
doi = "10.1016/S0009-9120(96)00100-2",
language = "English (US)",
volume = "29",
pages = "541--547",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Comparison of four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors

AU - Datta, Pradip

AU - Hinz, Vicki

AU - Klee, George

PY - 1996/12

Y1 - 1996/12

N2 - Objectives: Comparison of a new monoclonal digoxin assay with three polyclonal digoxin assays for their cross-reactivity to digoxin-like immunoreactive factors (DLIF) and digoxin metabolites. Design and Methods: Sixty-six nondigitalized patient samples from 5 different groups: neonates, women in 3rd trimester pregnancy, and patients with liver or renal diseases, or undergoing organ transplants, and 139 samples from digoxin-treated patients of 4 categories (hospital sick, liver, renal, and outpatients) were compared in 4 different digoxin assays: (a) ACS(TM) Digoxin (ACS) developed for the automated chemiluminescent Ciba Corning ACS 180® system, (b) Baxter Stratus(TM) (Stratus, a fluoroimmunoassay), (c) Ciba-Corning Magic(TM) (Magic, a radioimmunoassay), and (d) an in-house radioimmunoassay (RIA). The ACS(TM) and RIA were also compared for their cross-reactivity to four principal digoxin metabolites. Results and Conclusion: Among the nondigitalized specimens, no significant DLIF interference was found for all 4 assays among the pregnant women or liver and transplant patients. However, the neonates registered high DLIF interference with Magic(TM) and RIA, but none for ACS(TM) or Stratus(TM). DLIF interference in renal samples was highest in the Magic assay and lowest in RIA. Among the specimens with digoxin, a higher number of discrepant samples were found from the sick patients than from outpatients. In 75% of such discrepant samples, the ACS(TM) result was less than other assay results, suggesting DLIF as the probable cause. The two assays differed most in their cross-reactivity to the deglycated metabolites, digoxigenin and its mono-digitoxoside.

AB - Objectives: Comparison of a new monoclonal digoxin assay with three polyclonal digoxin assays for their cross-reactivity to digoxin-like immunoreactive factors (DLIF) and digoxin metabolites. Design and Methods: Sixty-six nondigitalized patient samples from 5 different groups: neonates, women in 3rd trimester pregnancy, and patients with liver or renal diseases, or undergoing organ transplants, and 139 samples from digoxin-treated patients of 4 categories (hospital sick, liver, renal, and outpatients) were compared in 4 different digoxin assays: (a) ACS(TM) Digoxin (ACS) developed for the automated chemiluminescent Ciba Corning ACS 180® system, (b) Baxter Stratus(TM) (Stratus, a fluoroimmunoassay), (c) Ciba-Corning Magic(TM) (Magic, a radioimmunoassay), and (d) an in-house radioimmunoassay (RIA). The ACS(TM) and RIA were also compared for their cross-reactivity to four principal digoxin metabolites. Results and Conclusion: Among the nondigitalized specimens, no significant DLIF interference was found for all 4 assays among the pregnant women or liver and transplant patients. However, the neonates registered high DLIF interference with Magic(TM) and RIA, but none for ACS(TM) or Stratus(TM). DLIF interference in renal samples was highest in the Magic assay and lowest in RIA. Among the specimens with digoxin, a higher number of discrepant samples were found from the sick patients than from outpatients. In 75% of such discrepant samples, the ACS(TM) result was less than other assay results, suggesting DLIF as the probable cause. The two assays differed most in their cross-reactivity to the deglycated metabolites, digoxigenin and its mono-digitoxoside.

KW - Antibodies

KW - Cross-reactivity

KW - Digoxin immunoassays

KW - Digoxin-like immunoreactive factors

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=0030561279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030561279&partnerID=8YFLogxK

U2 - 10.1016/S0009-9120(96)00100-2

DO - 10.1016/S0009-9120(96)00100-2

M3 - Article

C2 - 8939401

AN - SCOPUS:0030561279

VL - 29

SP - 541

EP - 547

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 6

ER -